Zimmer Biomet Holdings, Inc.

Equities

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
132 USD -0.48% Intraday chart for Zimmer Biomet Holdings, Inc. +3.86% +8.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
3M Board Approves Healthcare Unit Spinoff -- Update DJ
Zimmer Biomet's ROSA Shoulder Replacement Platform Receives FDA Clearance MT
Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery CI
Zimmer Biomet Maintains Quarterly Dividend at $0.24 a Share, Payable by April 30 to Shareholders of Record March 29 MT
Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024 CI
Smith & Nephew Q4 Margin in Focus, Outlook Upgrade Likely, RBC Says MT
Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting CI
UBS Adjusts Zimmer Biomet Price Target to $109 From $105, Maintains Sell Rating MT
Deutsche Bank Adjusts Zimmer Biomet Price Target to $140 From $147, Maintains Hold Rating MT
Zimmer Biomet Seeks M&A CI
Transcript : Zimmer Biomet Holdings, Inc., Q4 2023 Earnings Call, Feb 08, 2024
Zimmer Biomet forecasts upbeat 2024 profit on steady medical devices demand RE
Zimmer Biomet Q4 Adjusted Earnings, Net Sales Increase; Issues 2024 Guidance MT
(ZBH) ZIMMER BIOMET HOLDINGS Expects Fiscal Year 2024 EPS Range $8.00 - $8.15 MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Posts Q4 Revenue $1.94B, vs. Street Est of $1.93B MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Reports Q4 EPS $2.20, vs. Street Est of $2.16 MT
Tranche Update on Zimmer Biomet Holdings, Inc.'s Equity Buyback Plan announced on February 24, 2016. CI
Zimmer Biomet Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zimmer Biomet Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 CI
North American Morning Briefing : S&P 500 to Open -2- DJ
MORNING BID AMERICAS-Record S&P500 eyes 5,000, China deflated RE
UBS Raises Zimmer Biomet Price Target to $105 From $99, Maintains Sell Rating MT
RBC Raises Price Target on Zimmer Biomet Holdings to $140 From $134, Keeps Outperform Rating MT
Transcript : Zimmer Biomet Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM
Chart Zimmer Biomet Holdings, Inc.
More charts
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
132 USD
Average target price
136.6 USD
Spread / Average Target
+3.52%
Consensus